Eli Lilly CDR (CAD Hedged)
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 43K
- Market Cap
- $859.4B
- Introduction
Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.
Study of Gemcitabine/Platinum +/- Cetuximab as First-Line Treatment for Patients With Advanced/Metastatic Non-Small Cell Lung Cancer
- Conditions
- Non-Small-Cell Lung Carcinoma
- Interventions
- First Posted Date
- 2005-06-02
- Last Posted Date
- 2015-10-28
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 120
- Registration Number
- NCT00112346
- Locations
- 🇨🇦
Local Institution, Greenfield Park, Quebec, Canada
Study of Taxane/Carboplatin +/- Cetuximab as First-Line Treatment for Patients With Advanced/Metastatic Non-Small Cell Lung Cancer
- Conditions
- Non-Small-Cell Lung Carcinoma
- Interventions
- First Posted Date
- 2005-06-02
- Last Posted Date
- 2015-12-24
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 755
- Registration Number
- NCT00112294
- Locations
- 🇺🇸
Local Institution, Madison, Wisconsin, United States
Study of Erbitux™ (Cetuximab) in Pediatric Patients With Refractory Solid Tumors
- First Posted Date
- 2005-05-09
- Last Posted Date
- 2015-12-24
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 48
- Registration Number
- NCT00110357
- Locations
- 🇺🇸
Phoenix Children'S Hospital, Phoenix, Arizona, United States
🇺🇸University Of Arizona Health Sciences Center, Tucson, Arizona, United States
🇺🇸The Children'S Hospital, Denver, Colorado, United States
Comparing Pre-Mixed Insulin With Insulin Glargine Combined With Rapid-Acting Insulin in Patients With Type 2 Diabetes
- Conditions
- Diabetes Mellitus, Type 2
- First Posted Date
- 2005-05-09
- Last Posted Date
- 2007-11-27
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 300
- Registration Number
- NCT00110370
- Locations
- 🇵🇷
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern time (UTC/GMT - 5 hours, EST) or speak with your personal physician., Toa Baja, Puerto Rico
Study of Pemetrexed in the Treatment of Patients With Ovarian Cancer Who Have Failed Prior Platinum-Based Chemotherapy
- Conditions
- Ovarian NeoplasmsPrimary Peritoneal Cancer
- First Posted Date
- 2005-04-25
- Last Posted Date
- 2007-05-17
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 100
- Registration Number
- NCT00109096
- Locations
- 🇬🇧
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Sutton, United Kingdom
🇪🇸For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri 9 AM to 5 PM Eastern time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Valencia, Spain
Duloxetine Versus Placebo in the Prevention of Recurrence of Major Depressive Disorder
- First Posted Date
- 2005-03-21
- Last Posted Date
- 2009-07-28
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 514
- Registration Number
- NCT00105989
- Locations
- 🇸🇪
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Sundsvall, Sweden
Pemetrexed as the First Treatment in Advanced or Metastatic Breast Cancer
- Conditions
- Breast CancerBreast Neoplasms, MaleCarcinoma, Ductal
- Interventions
- First Posted Date
- 2005-03-21
- Last Posted Date
- 2009-06-01
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 37
- Registration Number
- NCT00106002
- Locations
- 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Dallas, Texas, United States
Enzastaurin as Second and Third-Line Treatment for Non-Small Cell Lung Cancer.
- Conditions
- Non-Small-Cell Lung Carcinoma
- First Posted Date
- 2005-03-07
- Last Posted Date
- 2007-05-01
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 50
- Registration Number
- NCT00105092
- Locations
- 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern time (UTC/GMT - 5 hours, EST) or speak with your personal physician., Houston, Texas, United States
Olanzapine Versus Aripiprazole in the Treatment of Acutely Ill Patients With Schizophrenia
- Conditions
- Schizophrenia
- First Posted Date
- 2005-02-11
- Last Posted Date
- 2007-11-06
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 600
- Registration Number
- NCT00103571
- Locations
- 🇵🇷
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. test, Rio Piedras, Puerto Rico
Pemetrexed and Best Supportive Care Versus Placebo and Best Supportive Care in Non-Small Cell Lung Cancer (NSCLC)
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2005-02-02
- Last Posted Date
- 2014-12-29
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 663
- Registration Number
- NCT00102804
- Locations
- 🇹🇷
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Izmir, Turkey